Pharmacogenetic effect of ADRB2 gene polymorphism on therapeutic response in chronic obstructive pulmonary disease
https://doi.org/10.18093/0869-0189-2013-0-3-21-24
Abstract
Summary. The purpose of this study was to evaluate effect of β2-adrenergic receptor gene polymorphisms on therapeutic response to β2-agonists and inhaled corticosteroids during 6-month therapy of chronic obstructive pulmonary disease (COPD). In 146 patients with stable COPD, polymorphisms of the amino acid positions 16 (Arg16/Gly16) and 27 (Gln27/Glu27) in the ADRB2 gene were assessed by allele-specific polymerase chain reaction. Gly16-Glu27-haplotype was associated with improvements in lung function, quality of life, and exercise tolerance after 6 months of combined treatment with long-acting β2-agonists and inhaled corticosteroids.
About the Authors
M. Kh. Mustafina
ГБОУ ВПО "Первый МГМУ им. И.М.Сеченова"
Russian Federation
Russian Federation
O. A. Tsvetkova
ГБОУ ВПО "Первый МГМУ им. И.М.Сеченова"
Russian Federation
Russian Federation
References
1. Global initiative for chronic obstructive lung disease (GOLD). [Электронный ресурс]. Global strategy for the diagnosis, management of chronic obstructive pulmonary disease (Updated 2010). http: www.goldcopd.com (Date last updated: November 2010).
2. Murray C.J., Lopez A.D. Global mortality, disability, and the contribution of risk factors: Global burden of disease study. Lancet 1997; 349 (9063): 1436–1442.
3. Чучалин А.Г. (ред.). Хроническая обструктивная болезнь легких: практическое руководство для врачей. М.: 2004.
4. Визель А.А., Визель И.Ю. Хроническая обструктивная болезнь легких: воспаление как ключевая проблема. Практ. Мед. 2009; 3 (35): 22?24.
5. Ноников В.Е. Хроническая обструктивная болезнь легких: современные подходы к терапии. Consilium Medicum 2001; 3 (12): 584–587.
6. Hall I.P. β2-adrenoceptor polymorphisms: are they clinically important? Thorax 1996; 51: 351–353.
7. Сычев Д.А., Муслимова О.В., Гаврисюк Е.В. и др. Фармакогенетические технологии персонализированной медицины: оптимизация применения лекарственных средств. Terra Medica 2011; 1: 4–9.
8. Thomsen M., Nordestgaard B.G. β2-Adrenergic receptor polymorphisms, asthma and COPD: two large populationbased studies. Eur. Respir. J. 2012; 39: 558–566.
9. Гланц С. Медико-биологическая статистика. Пер. с англ. М.: Практика; 1998.
10. Hizawa N., Makita H., Nashra Y. et al. Beta2-adrenergic receptor genetic polymorphisms and short-term bronchodilator responses in patients with COPD. Chest 2007; 132 (5): 1485–1486.
11. Bleecker E.R., Meyers D.A. ADRB2 Polymorphism and budesonide / formoterol response in chronic obstructive pulmonary disease. Chest 2012; 142 (2):320–328.
12. Kim W.J., Oh Y.M., Sung J. et al. Lung function response to 12-week treatment with combined inhalation of long-acting β2-agonist and glucocorticoid according to ADRB2 polymorphism in patients with chronic obstructive pulmonary disease. Lung 2008; 186 (6): 381–386.
Review
For citations:
Mustafina M.Kh., Tsvetkova O.A. Pharmacogenetic effect of ADRB2 gene polymorphism on therapeutic response in chronic obstructive pulmonary disease. PULMONOLOGIYA. 2013;(3):21-24. (In Russ.) https://doi.org/10.18093/0869-0189-2013-0-3-21-24
Views:
739
Email this article 